{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:35:21Z","timestamp":1773293721937,"version":"3.50.1"},"reference-count":56,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T00:00:00Z","timestamp":1599523200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2018R1C1B5085620"],"award-info":[{"award-number":["2018R1C1B5085620"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0238725","type":"journal-article","created":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T17:31:10Z","timestamp":1599586270000},"page":"e0238725","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Long-term treatment response after intravitreal bevacizumab injections for patients with central serous chorioretinopathy"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7675-0180","authenticated-orcid":true,"given":"Hae Min","family":"Kang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeong Hoon","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyoung Jun","family":"Koh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Chul","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2020,9,8]]},"reference":[{"issue":"2","key":"pone.0238725.ref001","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1600-0420.2007.00889.x","article-title":"Central serous chorioretinopathy.","volume":"86","author":"M Wang","year":"2008","journal-title":"Acta Ophthalmologica"},{"issue":"3","key":"pone.0238725.ref002","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ajo.2009.11.017","article-title":"Central serous chorioretinopathy: a personal perspective","volume":"149","author":"LA Yannuzzi","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"pone.0238725.ref003","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.preteyeres.2015.05.003","article-title":"Central serous chorioretinopathy: recent findings and new physiopathologic hypothesis.","volume":"48","author":"A Daruich","year":"2015","journal-title":"Prog Retin Eye Res"},{"issue":"2","key":"pone.0238725.ref004","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1442-9071.2012.02848.x","article-title":"Central serous chorioretinopathy: a review of epidemiology and pathophysiology.","volume":"41","author":"G Liew","year":"2013","journal-title":"Clin Exp Ophthalmol"},{"issue":"6","key":"pone.0238725.ref005","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1136\/bjophthalmol-2018-312431","article-title":"Patient characteristics and risk factors for central serous chorioretinopathy: an analysis of 811 patients","volume":"103","author":"MG Ersoz","year":"2019","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"pone.0238725.ref006","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0161-6420(89)32810-7","article-title":"Long-term follow-up of idiopathic central serous chorioretinopathy by fluorescence angiography","volume":"96","author":"R Levine","year":"1989","journal-title":"Ophthalmology"},{"issue":"3","key":"pone.0238725.ref007","first-page":"131","article-title":"Idiopathic serous chorioretinopaty.","volume":"46","author":"D Hussain","year":"1998","journal-title":"Indian J Ophthalmol"},{"issue":"3","key":"pone.0238725.ref008","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/ICU.0b013e3283459826","article-title":"Review and update of central serous chorioretinopathy.","volume":"22","author":"A Ross","year":"2011","journal-title":"Curr Opin Ophthalmol"},{"issue":"1","key":"pone.0238725.ref009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00006982-200302000-00001","article-title":"Cystoid macular degeneration in chronic central serous chorioretinopathy.","volume":"23","author":"T Iida","year":"2003","journal-title":"Retina"},{"issue":"1","key":"pone.0238725.ref010","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ajo.2004.08.037","article-title":"The foveal photoreceptor layer and visual acuity loss in central serous chorioretinopathy","volume":"139","author":"FC Piccolino","year":"2005","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"pone.0238725.ref011","first-page":"529","article-title":"Long-term follow-up of a prospective trial of argon laser photocoagulation in the treatment of central serous retinopathy","volume":"95","author":"L Ficker","year":"1988","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"pone.0238725.ref012","first-page":"787","article-title":"Retinal atrophy in idiopathic central serous chorioretinopathy","volume":"133","author":"MS Wang","year":"2002","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"pone.0238725.ref013","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3341\/kjo.2011.25.2.90","article-title":"Factors influencing the visual acuity of chronic central serous chorioretinopathy.","volume":"25","author":"YY Kim","year":"2011","journal-title":"Korean J Ophthalmol."},{"key":"pone.0238725.ref014","article-title":"An international collaborative evaluation of central serous chorioretinopathy: different therapeutic approaches and review of literature. The European Vitreoretinal Society central serous chorioretinopathy study.","author":"MR Romano","year":"2019","journal-title":"Acta Ophthalmol"},{"issue":"2","key":"pone.0238725.ref015","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3109\/02713680903428306","article-title":"Intravitreal bevacizumab in treatment of idiopathic persistent central serous chorioretinopathy: a prospective, controlled clinical study","volume":"35","author":"O Artunay","year":"2010","journal-title":"Curr Eye Res"},{"issue":"7","key":"pone.0238725.ref016","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1089\/jop.2015.0149","article-title":"Efficacy of intravitreal bevacizumab for recurrent central serous chorioretinopathy in patients who had previously responded well to the same therapy","volume":"32","author":"KH Shin","year":"2016","journal-title":"J Ocul Pharmacol Ther"},{"issue":"6","key":"pone.0238725.ref017","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/eye.2015.58","article-title":"Clinical characteristics of responders to intravitreal bevacizumab in central serous chorioretinopathy patients.","volume":"29","author":"GA Kim","year":"2015","journal-title":"Eye"},{"issue":"1","key":"pone.0238725.ref018","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/IAE.0000000000001917","article-title":"Twelve-month efficacy of intravitreal bevacizumab injection for chronic, atypical, or recurrent central serous chorioretinopathy.","volume":"39","author":"YR Chung","year":"2019","journal-title":"Retina"},{"issue":"4","key":"pone.0238725.ref019","first-page":"176","article-title":"The effect of intravitreal bevacizumab on central serous chorioretinopathy.","volume":"7","author":"A Maleki","year":"2018","journal-title":"Med Hypothesis Discov Innov Ophthalmol"},{"issue":"4","key":"pone.0238725.ref020","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1177\/112067210901900415","article-title":"Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy.","volume":"19","author":"KB Schaal","year":"2009","journal-title":"Eur J Ophthalmol"},{"issue":"1","key":"pone.0238725.ref021","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000314709","article-title":"Results of one-year follow-up examinations after intravitreal bevacizumab administration for chronic central serous chorioretinopathy.","volume":"225","author":"M Inoue","year":"2011","journal-title":"Ophthalmologica"},{"issue":"1","key":"pone.0238725.ref022","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/IAE.0b013e3181bcf0b4","article-title":"Intravitreal bevacizumab injection for central serous chorioretinopathy.","volume":"30","author":"SJ Lim","year":"2010","journal-title":"Retina"},{"issue":"7","key":"pone.0238725.ref023","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s00417-010-1581-9","article-title":"The efficacy of intravitreal bevacizumab for idiopathic central serous chorioretinopathy","volume":"249","author":"JW Lim","year":"2011","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"12","key":"pone.0238725.ref024","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/eye.2013.236","article-title":"Lack of positive effect of intravitreal bevacizumab in central serous chorioretinopathy: meta-analysis and review.","volume":"27","author":"YR Chung","year":"2013","journal-title":"Eye"},{"issue":"1","key":"pone.0238725.ref025","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1089\/jop.2012.0072","article-title":"The efficacy of intravitreal bevacizumab for acute central serous chorioretinopathy","volume":"29","author":"E Aydin","year":"2013","journal-title":"J Ocul Pharmacol Ther"},{"key":"pone.0238725.ref026","doi-asserted-by":"crossref","first-page":"125","DOI":"10.4103\/abr.abr_193_15","article-title":"Effect of intravitreal injection of bevacizumab on acute central serous chorioretinopathy patients who visited Feiz hospital during 2014\u20132015 period","volume":"6","author":"MR Akhlaghi","year":"2017","journal-title":"Adv Biomed Res"},{"issue":"1","key":"pone.0238725.ref027","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4103\/2008-322X.180700","article-title":"Intravitreal bevacizumab for treatment of central serous chorioretinopathy.","volume":"11","author":"C \u00dcnl\u00fc","year":"2016","journal-title":"J Ophthalmic Vis Res"},{"issue":"3","key":"pone.0238725.ref028","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3341\/kjo.2010.24.3.155","article-title":"The effect of intravitreal bevacizumab in patients with acute central serous chorioretinopathy.","volume":"24","author":"JW Lim","year":"2010","journal-title":"Korean J Ophthalmol"},{"issue":"6","key":"pone.0238725.ref029","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1136\/bjophthalmol-2014-306018","article-title":"A prospective pilot study of intravitreal aflibercept for the treatment of chronic central serous chorioretinopathy: the CONTAIN study","volume":"99","author":"JD Pitcher","year":"2015","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"pone.0238725.ref030","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000345495","article-title":"Intravitreal ranibizumab for acute central serous chorioretinopathy.","volume":"229","author":"M Kim","year":"2013","journal-title":"Ophthalmologica"},{"issue":"10","key":"pone.0238725.ref031","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1089\/jop.2014.0043","article-title":"Success of ranibizumab in central serous chorioretinopathy resistant to bevacizumab","volume":"30","author":"A Altun","year":"2014","journal-title":"J Ocul Pharmacol Ther"},{"issue":"5","key":"pone.0238725.ref032","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.ajo.2011.04.008","article-title":"A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy","volume":"152","author":"SH Bae","year":"2011","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"pone.0238725.ref033","doi-asserted-by":"crossref","first-page":"e594","DOI":"10.1111\/aos.12482","article-title":"Systemic review and meta-analysis on photodynamic therapy in central serous chorioretinopathy.","volume":"92","author":"J Ma","year":"2014","journal-title":"Acta phthalmol."},{"issue":"2","key":"pone.0238725.ref034","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.ophtha.2013.09.024","article-title":"Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy","volume":"121","author":"SH Bae","year":"2014","journal-title":"Ophthalmology"},{"issue":"7","key":"pone.0238725.ref035","doi-asserted-by":"crossref","first-page":"e0181479","DOI":"10.1371\/journal.pone.0181479","article-title":"Long-term prognostic factors of chronic central serous chorioretinopathy after half-dose photodynamic therapy: a 3-year follow-up study.","volume":"12","author":"F Haga","year":"2017","journal-title":"PLoS One"},{"issue":"6","key":"pone.0238725.ref036","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1097\/00006982-200312000-00002","article-title":"Photodynamic therapy for chronic central serous chorioretinopathy.","volume":"23","author":"F Cardillo Piccolino","year":"2003","journal-title":"Retina"},{"issue":"6","key":"pone.0238725.ref037","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.ajo.2004.01.043","article-title":"Chronic central serous chorioretinopathy: photodynamic therapy","volume":"137","author":"M Taban","year":"2004","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"pone.0238725.ref038","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.ajo.2003.11.079","article-title":"Transient reduction in retinal function revealed by multifocal electroretinogram after photodynamic therapy","volume":"137","author":"TY Lai","year":"2004","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"pone.0238725.ref039","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1167\/iovs.05-0838","article-title":"Ocular changes after photodynamic therapy","volume":"47","author":"R Tzekov","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"9","key":"pone.0238725.ref040","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1097\/IAE.0b013e3181d8e7fe","article-title":"Aqueous humor and plasma levels of vascular endothelial growth factor and interleukin-8 in patients with central serous chorioretinopathy.","volume":"30","author":"JW Lim","year":"2010","journal-title":"Retina"},{"key":"pone.0238725.ref041","unstructured":"Shin MC, Lim JW. Concentration of cytokines in the aqueous humor of patients with central serous chorioretinopathy."},{"issue":"3","key":"pone.0238725.ref042","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/cxo.12125","article-title":"Cytokine levels of the aqueous humour in central serous chorioretinopathy","volume":"97","author":"SH Jung","year":"2014","journal-title":"Clin Exp Optom"},{"issue":"15","key":"pone.0238725.ref043","doi-asserted-by":"crossref","first-page":"5924","DOI":"10.1167\/iovs.18-25517","article-title":"Association of upregulated angiogenic cytokines with choroidal abnormalities in chronic central serous chorioretinopathy","volume":"59","author":"N Terao","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"pone.0238725.ref044","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.ajo.2007.03.007","article-title":"Ultrastructural findings in primate eye after intravitreal injection of bevacizumab","volume":"143","author":"S Peters","year":"2007","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"pone.0238725.ref045","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1136\/bjo.2006.109702","article-title":"Antipermeability and antiproliferative effects of standard and frozen bevacizumab on choroidal endothelial cells","volume":"91","author":"S Peters","year":"2007","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"pone.0238725.ref046","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/IAE.0000000000001502","article-title":"Subfoveal choroidal thickness and vascular diameter in active and resolved central serous chorioretinopathy.","volume":"38","author":"YR Chung","year":"2018","journal-title":"Retina"},{"issue":"9","key":"pone.0238725.ref047","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1097\/IAE.0000000000000557","article-title":"Subfoveal choroidal thickness changes in treated idiopathic central serous chorioretinopathy and their association with recurrence.","volume":"35","author":"DY Kim","year":"2015","journal-title":"Retina"},{"issue":"3","key":"pone.0238725.ref048","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3341\/kjo.2015.29.3.160","article-title":"The association between choroidal thickness variations and response to intravitreal bevacizumab in central serous chorioretinopathy.","volume":"29","author":"DY Kim","year":"2015","journal-title":"Korean J Ophthalmol"},{"issue":"1","key":"pone.0238725.ref049","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3928\/23258160-20150101-04","article-title":"Choroidal thickness and choroidal blood flow after intravitreal bevacizumab injection in eyes with central serous chorioretinopathy","volume":"46","author":"M Okamoto","year":"2015","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"5","key":"pone.0238725.ref050","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1177\/112067211002000524","article-title":"Intravitreal ranibizumab in the treatment of choroidal neovascularization associated with idiopathic central serous chorioretinopathy.","volume":"20","author":"L Konstantinidis","year":"2010","journal-title":"Eur J Ophthalmol"},{"issue":"4","key":"pone.0238725.ref051","doi-asserted-by":"crossref","first-page":"503","DOI":"10.5301\/EJO.2011.6290","article-title":"Intravitreal bevacizumab to treat choroidal neovascularization following photodynamic therapy in central serous choroidopathy.","volume":"21","author":"JA Montero","year":"2011","journal-title":"Eur J Ophthalmol."},{"issue":"8","key":"pone.0238725.ref052","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.ophtha.2012.02.021","article-title":"Assessment of macular choroidal angiographic changes in central serous chorioretinopathy","volume":"119","author":"P Jirarattanasopa","year":"2012","journal-title":"Ophthalmology"},{"issue":"1","key":"pone.0238725.ref053","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0002-9394(14)70531-8","article-title":"Choroidal capillary and venous congestion in central serous chorioretinopathy","volume":"121","author":"C Prunte","year":"1996","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"pone.0238725.ref054","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1001\/archopht.1994.01090200063023","article-title":"Digital indocyanine green videoangiography of central serous chorioretinopathy.","volume":"112","author":"DR Guyer","year":"1994","journal-title":"Arch Ophthamol"},{"issue":"9","key":"pone.0238725.ref055","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1097\/IAE.0b013e318156db8a","article-title":"The natural history of pigment epithelial detachment associated with central serous chorioretinopathy","volume":"27","author":"SS Mudvari","year":"2007","journal-title":"Retina"},{"issue":"1","key":"pone.0238725.ref056","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00006982-200202000-00004","article-title":"Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy.","volume":"22","author":"RH Loo","year":"2002","journal-title":"Retina"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0238725","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T17:32:15Z","timestamp":1599586335000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0238725"}},"subtitle":[],"editor":[{"given":"Demetrios G.","family":"Vavvas","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,9,8]]},"references-count":56,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,9,8]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0238725","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,8]]}}}